1233403-74-1

Basic information

• Product Name: 2-(4-hydroxyphenyl)-4,6-bis(morpholin-4-yl)-1,3,5-triazine
• Synonyms: 2-(4-hydroxyphenyl)-4,6-bis(morpholin-4-yl)-1,3,5-triazine
• CAS NO: 1233403-74-1
• Molecular Weight: 343.385
• Mol File: 1233403-74-1.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2-(4-hydroxyphenyl)-4,6-bis(morpholin-4-yl)-1,3,5-triazine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-hydroxyphenyl)-4,6-bis(morpholin-4-yl)-1,3,5-triazine(1233403-74-1)
• EPA Substance Registry System: 2-(4-hydroxyphenyl)-4,6-bis(morpholin-4-yl)-1,3,5-triazine(1233403-74-1)

Safety Data

• Hazardous Substances Data: 1233403-74-1(Hazardous Substances Data)

Upstream product

• 7597-22-0 2-chloro-4,6-di-morpholin-4-yl-[1,3,5]triazine 
• 71597-85-8 (p-hydroxyphenyl)boronic acid 

Relevant articles and documents

Discovery of a novel HDAC3 selective inhibitor and its evaluation in lymphoma model

Histone deacetylase (HDAC) inhibition is a potentially attractive approach to cancer therapy. A number of HDAC inhibitors are in clinical development stages for the treatment of cancer as well as immune and inflammatory disorders. Although there are several approved HDAC inhibitors by the US FDA, they show a broad inhibitory spectrum against HDAC subfamily. Herein, we synthesized a series of novel hydroxamate analogs, and evaluated them with lymphoma cancer cell. Conclusively, we identified an HDAC3 selective inhibitor which shows good anticancer activity for the lymphoma model, as well as a good drug metabolism and pharmacokinetics (DMPK) profile.

NOVEL HYDROXAMATE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF CANCER CONTAINING THE SAME

The present invention relates to novel hydroxamate derivatives or pharmaceutically acceptable salts thereof, and a pharmaceutical composition comprising the same as active components for preventing or treating cancers. The novel hydroxamate derivatives or pharmaceutically acceptable salts thereof selectively inhibit histone deacetylase-3 which is involved in delivering signals to control a DNA packing structure in cells, and thus resolve toxicity limit of a conventional pan-HDAc inhibitor while effectively inhibiting growth of cancer cells.COPYRIGHT KIPO 2016